Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Huang, W. Articles by Schapiro, M. B. Search for Related Content PubMed Citation Articles by Huang, W. Articles by Schapiro, M. B. Neurotransmitters Mental Retardation Alzheimer's Disease MRS Neurodegeneration

High Brain myo-Inositol Levels in the Predementia Phase of Alzheimer’s Disease in Adults With Down’s Syndrome: A ¹H MRS Study

OBJECTIVE: An extra portion of chromosome 21 in Down’s syndrome leads to a dementia in later life that is phenotypically similar to Alzheimer’s disease. Down’s syndrome therefore represents a model for studying preclinical stages of Alzheimer’s disease. Markers that have been investigated in symptomatic Alzheimer’s disease are myo-inositol and N-acetylaspartate. The authors investigated whether abnormal brain levels of myo-inositol and other metabolites occur in the preclinical stages of Alzheimer’s disease associated with Down’s syndrome. METHOD: The authors used ¹H magnetic resonance spectroscopy (MRS) with external standards to measure absolute brain metabolite concentrations in 19 nondemented adults with Down’s syndrome and 17 age- and sex-matched healthy comparison subjects. RESULTS: Concentrations of myo-inositol and choline-containing compounds were significantly higher in the occipital and parietal regions of the adults with Down’s syndrome than in the comparison subjects. Within the Down’s syndrome group, older subjects (42–62 years, N=11) had higher myo-inositol levels than younger subjects (28–39 years, N=8). Older subjects in both groups had lower N-acetylaspartate levels than the respective younger subjects, although this old-young difference was not greater in the Down’s syndrome group. CONCLUSIONS: The approximately 50% higher level of myo-inositol in Down’s syndrome suggests a gene dose effect of the extra chromosome 21, where the human osmoregulatory sodium/myo-inositol cotransporter gene is located. The even higher myo-inositol level in older adults with Down’s syndrome extends to the predementia phase earlier findings of high myo-inositol levels in symptomatic Alzheimer’s disease.

This article has been cited by other articles:

				K. Kantarci, D. S. Knopman, D. W. Dickson, J. E. Parisi, J. L. Whitwell, S. D. Weigand, K. A. Josephs, B. F. Boeve, R. C. Petersen, and C. R. Jack Jr Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem 1H MR Spectroscopy Metabolite Measurements Radiology, July 1, 2008; 248(1): 210 - 220. [Abstract] [Full Text] [PDF]

				K KANTARCI 1H Magnetic resonance spectroscopy in dementia Br. J. Radiol., December 1, 2007; 80(Special_Issue_2): S146 - S152. [Abstract] [Full Text] [PDF]

				A. K. Godbolt, A. D. Waldman, D. G. MacManus, J. M. Schott, C. Frost, L. Cipolotti, N. C. Fox, and M. N. Rossor MRS shows abnormalities before symptoms in familial Alzheimer disease Neurology, March 14, 2006; 66(5): 718 - 722. [Abstract] [Full Text] [PDF]

				A. J. Ross, P. S. Sachdev, W. Wen, and H. Brodaty Longitudinal changes during aging using proton magnetic resonance spectroscopy. J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2006; 61(3): 291 - 298. [Abstract] [Full Text] [PDF]

				F. Beacher, A. Simmons, E. Daly, V. Prasher, C. Adams, M. L. Margallo-Lana, R. Morris, S. Lovestone, K. Murphy, and D. G. M. Murphy Hippocampal Myo-inositol and Cognitive Ability in Adults With Down Syndrome: An In Vivo Proton Magnetic Resonance Spectroscopy Study Arch Gen Psychiatry, December 1, 2005; 62(12): 1360 - 1365. [Abstract] [Full Text] [PDF]

				Y.-Y. Hsu, A.-T. Du, N. Schuff, and M. W. Weiner Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy in Dementias J Geriatr Psychiatry Neurol, September 1, 2001; 14(3): 145 - 166. [Abstract] [PDF]

				W. Huang, G. E. Alexander, L. Chang, H. U. Shetty, J. S. Krasuski, S. I. Rapoport, and M. B. Schapiro Brain metabolite concentration and dementia severity in Alzheimer's disease: A 1H MRS study Neurology, August 28, 2001; 57(4): 626 - 632. [Abstract] [Full Text] [PDF]

				J. C.W. Brooks, N. Roberts, G. J. Kemp, M. A. Gosney, M. Lye, and G. H. Whitehouse A Proton Magnetic Resonance Spectroscopy Study of Age-related Changes in Frontal Lobe Metabolite Concentrations Cereb Cortex, July 1, 2001; 11(7): 598 - 605. [Abstract] [Full Text] [PDF]

				S. I. Rapoport Functional brain imaging to identify affected subjects genetically at risk for Alzheimer's disease PNAS, May 23, 2000; 97(11): 5696 - 5698. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us